IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,280.00
-160.00 (-2.94%)
May 20, 2026, 3:30 PM KST
Market Cap74.01B -44.0%
Revenue (ttm)5.33B +56.4%
Net Income-7.93B
EPS-565.99
Shares Out14.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,949
Average Volume64,531
Open5,620.00
Previous Close5,440.00
Day's Range5,060.00 - 5,620.00
52-Week Range5,250.00 - 12,990.00
Betan/a
RSI24.83
Earnings Daten/a

About IMB Dx

IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis. It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2025, IMB Dx's revenue was 5.33 billion, an increase of 56.40% compared to the previous year's 3.41 billion. Losses were -7.93 billion, -17.15% less than in 2024.

Financial Statements